

30 **ABSTRACT**

31 **Background:** From the onset of the COVID-19 pandemic, an association between the
32 severity of COVID-19 and the presence of certain medical chronic conditions has been
33 suggested. However, unlike influenza and other viruses, the burden of the disease in
34 patients with asthma has been less evident.

35 **Objective:** This study aims at a better understanding of the burden of COVID-19 in
36 patients with asthma and the impact of asthma, its related comorbidities, and treatment
37 on the prognosis of COVID-19.

38 **Methods:** We analyzed clinical data from patients with asthma from January 1st to May
39 10th, 2020 using big data analytics and artificial intelligence through the SAVANA
40 *Managei*[®] clinical platform.

41 **Results:** Out of 71,192 patients with asthma, 1,006 (1.41%) suffered from COVID-19.
42 Compared to asthmatic individuals without COVID-19, patients with asthma and COVID-
43 19 were significantly older (55 vs. 42 years), predominantly female (66% vs. 59%), had
44 higher prevalence of hypertension, dyslipidemias, diabetes, and obesity, and smoked
45 more frequently. Contrarily, allergy-related factors such as rhinitis and eczema were less
46 frequent in asthmatic patients with COVID-19 ($P < .001$). Higher prevalence of
47 hypertension, dyslipidemia, diabetes, and obesity was also confirmed in those patients
48 with asthma and COVID-19 who required hospital admission. The percentage of
49 individuals using inhaled corticosteroids (ICS) was lower in patients who required
50 hospitalization due to COVID-19, as compared to non-hospitalized patients (48.3% vs.
51 61.5%; OR: 0.58: 95% CI 0.44 - 0.77). During the study period, 865 (1.21%) patients with
52 asthma were being treated with biologics. Although these patients showed increased
53 severity and more comorbidities at the ear, nose, and throat (ENT) level, their hospital
54 admission rates due to COVID-19 were relatively low (0.23%). COVID-19 increased
55 inpatient mortality in asthmatic patients (2.29% vs 0.54%; OR 2.29: 95% CI 4.35 – 6.66).

56 **Conclusion:** Our results indicate that the number of COVID-19 cases in patients with
57 asthma has been low, although higher than the observed in the general population.
58 Patients with asthma and COVID-19 were older and were at increased risk due to
59 comorbidity-related factors. ICS and biologics are generally safe and may be associated
60 with a protective effect against severe COVID-19 infection.

61 INTRODUCTION

62 Asthma remains a global major challenge for public health. Affecting approximately 272
63 million people of all ages (4.5% of adults aged 18-50), asthma is one of the most common
64 chronic disorders worldwide (1,2). In the United States, it has been estimated that up to
65 12 million people experience an acute exacerbation of their asthma ever year, a quarter
66 of which require hospitalization (3). In Europe, asthma ranks 14th in terms of duration and
67 associated disability, and leads to an estimated cost of EUR 25 billion per year (4). In
68 Spain, 5% of adults and 10% of children have asthma. However, up to 50% of patients
69 remain undiagnosed. Indeed, 8.6% of adults (aged 18-70) and 14% of children show
70 asthma-related symptoms, being dyspnea and cough the most common (4,5). Yet,
71 between 60% and 70% of patients with asthma in Spain are not properly controlled (6,
72 7). This is critical since patients with uncontrolled asthma may generate ten times as
73 much direct and indirect costs than controlled patients (1).

74 The severity of the disease is related to uncontrolled bronchial asthma in many
75 patients; in other cases, worsening symptoms and asthma exacerbation are associated
76 with treatment-related variables (e.g., inappropriate treatment, lack of adherence) or with
77 the presence of underlying risk factors (6-8), most notably viral respiratory infection.
78 Asthma exacerbations caused by respiratory infections or other conditions have a
79 negative impact on the patient's health status and lead to worse prognosis.

80 COVID-19 is the disease caused by the severe acute respiratory syndrome
81 coronavirus 2 (SARS-CoV-2). Clinically, the severity of COVID-19 can vary from mild to
82 very severe, causing mortality in some patients (9,10). The ongoing COVID-19 pandemic
83 certainly represents a major challenge for health systems globally. Since the beginning
84 of the pandemic, an association between COVID-19 severity and chronic medical
85 conditions such as cardiovascular disease, diabetes mellitus, and high blood pressure
86 has been suggested. Unlike influenza and other seasonal viruses however, the impact
87 of COVID-19 in patients with asthma has been less evident (11-14). On the other hand,

88 the severity and mortality of COVID-19 has been strongly related with age. Although the
89 virus can infect individuals of all ages, most severe cases to date have been described
90 in adults 55 years and older, and in patients with the aforementioned comorbidities. In
91 this age group, patients typically have more than one chronic condition, particularly
92 endocrine-metabolic and cardiovascular diseases. With this background, it is imperative
93 to characterize the clinical course of SARS-CoV-2 infection in patients with asthma and
94 assess the impact of asthma and asthma-related comorbidities and treatment in COVID-
95 19-related outcomes.

96 Emerging and rapidly evolving diseases such as COVID-19 are best understood
97 using population-based registries containing real-world information (15). In this context,
98 combining real-world data with big data analytics has the potential to increase our
99 understanding of the effects of COVID-19 in patients with asthma and identify new
100 strategies and management options for therapeutic intervention. A relevant data source
101 with the above-mentioned characteristics is the clinical information contained in patients'
102 electronic health records (EHR).

103 Using the clinical information captured in the EHRs of patients with asthma and
104 COVID-19, here we aimed to a) describe the frequency and clinical characteristics of
105 these patients and b) understand the clinical impact of COVID-19 on the clinical course
106 of patients with asthma. To achieve the study objectives, we used big data analytics and
107 artificial intelligence (AI) through the SAVANA *Manager*[®] clinical platform (16-17).

108

109 **METHODS**

110 This was a multi-center, non-interventional, retrospective study using free-text data
111 captured in the EHRs of patients diagnosed of COVID-19. The study period was January
112 1, 2019 - May 10, 2020.

113 We followed the Strengthening the Reporting of Observational Studies in
114 Epidemiology (STROBE) guidelines for reporting observational studies (18). The study
115 was conducted in accordance with legal and regulatory requirements and followed
116 research practices described in the ICH Guidelines for Good Clinical Practice, the
117 Declaration of Helsinki in its latest edition, the Guidelines for Good
118 Pharmacoepidemiology Practice (GPP), and local regulations. Given the retrospective
119 and observational nature of the study, physicians' prescribing habits and patient
120 assignment to a specific therapeutic strategy were solely determined by the physician,
121 team, or hospital concerned. Likewise, a standard informed consent does not apply to
122 this study. All actions towards data protection were taken in accordance with the
123 European Data Protection authorities' code of good practice regarding big data projects
124 and the European General Data Protection Regulation (GDPR). This study was
125 approved by the Ethics and Research Committee of the University Hospital of
126 Guadalajara (Spain).

127 Clinical data from a total of 2,034,921 patients with available EHRs in the region
128 of Castilla La-Mancha (Spain) were explored. Data were collected from all available
129 services, including inpatient and outpatient departments, emergency room, and primary
130 care.

131 The information from EHRs was extracted with Natural Language Processing
132 (NLP) and AI techniques using SAVANA *Manager*[®], a powerful multilingual (natural
133 language) engine for the analysis of free-text clinical information. This software is able
134 to interpret any content included in electronic clinical records, regardless of the electronic
135 system in which it operates. Importantly, this tool can capture numerical values and
136 clinical notes and transform them into accessible variables, thus allowing for the reuse
137 of the information captured in large-scale collections of clinical records (i.e., big data).
138 The data extraction process has four distinct phases aimed at transferring and
139 aggregating the data into the study database, namely a) Acquisition: data acquisition is

140 the responsibility of the participating site, in close collaboration with SAVANA's
141 Information Technology staff. In compliance with the EU GDPR, data were anonymized
142 and transferred to SAVANA during this phase; b) Integration: In this phase, data were
143 integrated into the database; c) NLP processing: SAVANA's *EHRead*[®] technology
144 applied NLP techniques to analyze and extract the unstructured free-text information
145 written in large amounts of EHRs. The NLP output is a synthetic patient database, as the
146 software creates a patient database from scratch. This process ensures that this
147 information is inaccessible and makes traceability to individual patients impossible; and
148 d) Validation, consisting of a medical validation of the tool's output by doctors and
149 researchers.

150 The terminology used by SAVANA is based on multiple sources such as
151 SNOMED CT (19), which includes medical codes, concepts, synonyms, and definitions
152 regarding symptoms, diagnoses, body structures, and substances commonly used in
153 clinical documentation. Due to the novel methodological approach of this study, we
154 complemented our clinical findings with the assessment of *EHRead's* performance. This
155 evaluation was aimed at verifying the system's accuracy in identifying records that
156 contain mentions of asthma and COVID-19 and its related variables. For a
157 comprehensive description of the evaluation procedure, see (19). Briefly, the annotations
158 made by the medical experts were used to generate the gold standard to assess the
159 performance of *EHRead's* output; performance is calculated in terms of the standard
160 metrics of accuracy (P), recall (R), and their harmonic mean F-score (20).

161 All statistical analyses were conducted using SPSS software (V25.0). Unless
162 otherwise indicated, qualitative variables are expressed as absolute frequencies and
163 percentages, while quantitative variables are expressed as means and standard
164 deviations. For the assessment of statistical significance of numerical variables, we used
165 independent samples Student's T-tests or ANOVA. To measure the relative distribution

166 of patients assigned to different categories of qualitative variables, we used Chi² tests.
167 In all cases, a p value for statistical significance was set at 0.05.

168

169 **RESULTS**

170 We identified 71,192 patients with asthma during the study period (January 1, 2019 -
171 May 10, 2020). The search terms used to identify patients with bronchial asthma are
172 listed in **eTable 1**. For the linguistic evaluation of the variable 'asthma', we obtained
173 Precision, Recall, and F- Scores of 0.88, 0.75, and 0.81, respectively; these metrics
174 indicate that patients with asthma were properly identified within the target population.
175 The patient flowchart for asthmatics with and without COVID-19 is depicted in **Figure 1**.

176 Patients' age (mean ± SD) was 42 ± 20 years; 59% of patients were women.
177 Overall, 1,006 (1.41%) asthma patients were also diagnosed with COVID-19. *EHRead*
178 identified COVID-19 with a Precision of 0,99, a Recall of 0,75, and a F-Score of 0,93;
179 again, these results indicate that within our population with asthma, COVID-19 cases
180 were accurately identified. COVID-19 diagnosis was confirmed by PCR in 61% of
181 patients (n = 611); in the remaining cases, and considering the epidemiological context
182 of the pandemic in the study area between March and May 2020, diagnosis was based
183 on rapid serological tests or clinical, radiological, and/or analytical evaluation, Notably,
184 the percentage (95% CI) of patients diagnosed with COVID-19 in the population of
185 patients with asthma (1.41%; 1.33 – 1.50) was significantly higher than in the general
186 population of Castilla La-Mancha (Spain) (0.86%; 0.85 – 0.87), *P* <.001.

187 Patients with asthma who also had a diagnosis of COVID-19 were older,
188 predominantly women, and had higher prevalence rates of hypertension, dyslipidemia,
189 diabetes, obesity, and smoking habits than asthmatic individuals without COVID-19 (all
190 *P* <.05). By contrast, atopy-related factors such as rhinitis or eczema were significantly
191 more frequent in patients without COVID-19 (**Table 1**). The higher prevalence of

192 hypertension, dyslipidemia, diabetes, and obesity was further confirmed in those patients
193 requiring hospital admission, as compared with those who only required outpatient
194 management (**Table 2**).

195 The proportion of patients with asthma using inhaled corticosteroids (ICS) was
196 significantly lower in individuals requiring hospital admission (48.3% vs 61.5%)
197 respectively, with an OR (95% CI) of 0.58 (0.44 - 0.77). The most common diagnosis in
198 hospitalized patients was pneumonia (91% of patients; n = 239), with great variability of
199 radiological expression. Different diagnoses associated with respiratory failure but with
200 normal lung radiology (data not shown) were found in 9% (n = 24) of patients.

201 Regardless of previous ICS or bronchodilator use, a total of 865 patients in the
202 study population were being treated with biologics during the study period, due to
203 previous poor control of the disease (**Table 3**). Biologics-treated patients showed a high
204 frequency of rhinitis and polyposis (50% in both cases), and a greater number of
205 bronchospasm episodes before treatment onset with biologics. Despite increased
206 severity and comorbidity of symptoms at the ear, nose, and throat (ENT) level, the need
207 for COVID-19-related hospital admission in biologics-treated patients with asthma was
208 relatively marginal (0.23%; 0.03 – 0.83). This proportion markedly differs from the
209 observed in both the general population and in the population of patients with asthma
210 not being treated with biologics; in both cases 26% of patients required hospitalization
211 due to COVID-19. Only one patient undergoing treatment with biologics died; he was a
212 52-year-old male with high blood pressure, diabetes mellitus, and dyslipidemia.

213 Compared with information from patients with asthma available since January
214 2019, the data collected during the study period (January 1st to May 10th, 2020) show
215 that COVID-19 significantly increased in-hospital mortality in this population (0.54% vs
216 2.29%), with an associated OR (95% CI) of 4.35 (2.84 - 6.66). For both periods, in-
217 hospital mortality mainly affected elderly patients, with an average age (\pm SD) of 76 (\pm 12)
218 years in patients with both asthma and COVID-19, and 78 (\pm 17) in COVID-19-free

219 patients with asthma, $P < .001$); most of these patients were women in both study periods
220 (61% and 71%, respectively, and had previously diagnosed comorbidities (**Table 4**). On
221 the other hand, the age distribution (mean \pm SD) of patients without asthma who died
222 from COVID-19 was 79 ± 11 years, and 63% ($n = 296$) of them were male.

223

224 **DISCUSSION**

225 The WHO declared the COVID-19 outbreak a global pandemic on March 11, 2020. Ever
226 since, clinicians worldwide have been particularly concerned about the impact of
227 patients' preexisting chronic conditions (particularly lung and cardiovascular diseases)
228 on the course of this new disease. Whereas high blood pressure and diabetes have been
229 closely associated with increased frequency of cases and severity of COVID-19, care-
230 related data suggest that COVID-19 has not affected patients with asthma to nearly the
231 same extent (13,21-23).

232 To shed light on this question, we have applied big data analytics and AI to
233 analyze the clinical information of a large cohort of patients with asthma and COVID-19.
234 Big data applications in healthcare (specifically the use of new technologies to manage
235 and extract the complex data generated in large volumes of EHRs) is an inescapable
236 reality (24). Crucially, most of the information contained in EHRs is found in an
237 unstructured form (e.g., as free-text narratives or clinical notes). The use of big data
238 analytics and cutting-edge methods in the realm of AI (i.e., NLP, machine learning) now
239 allows for the extraction and analysis of this valuable information in real time. The
240 software use in the present study enable the rapid evaluation of the main indicators of
241 various clinical processes while avoiding the selection biases that occur in audit or case
242 series studies, where only specialized centers and medical professionals participate in
243 the study. Importantly, the Spanish Autonomous Community of Castilla-La Mancha has
244 different features that optimize the use of this technology to analyze the clinical impact
245 of COVID-19 on patients with asthma. First, this region has been one of the most affected

246 by the pandemic in Spain, which in turn has been one of the most hard-hit countries in
247 Europe. Second, it has a good EHR system, which has been standardized and is shared
248 across all five provinces. Finally, the *SAVANA Manager*[®] tool is widely available in the
249 region, allowing access to large amounts of clinical information (25).

250 In the present study, we analyzed clinical data from the largest population of
251 asthma patients published to date (n = 71,192); 1,006 of these patients were diagnosed
252 with COVID-19. The study period was January 1, 2019-May 10, 2020. Although the
253 system allows us to analyze data from 2011 onwards, we selected this temporal cut-off
254 to include asthmatic patients with updated follow-up information and with the active form
255 of the disease.

256 The proportion of patients with both asthma and COVID-19 during the study
257 period was 1.41%, which is markedly higher than the 0.86% observed in the general
258 population. Although these data show a higher frequency of COVID-19 in patients with
259 asthma, the manifestation of the disease in this clinical population was not particularly
260 severe, with low rate of hospital admissions. In addition, this proportion is lower than the
261 reported for patients with other chronic diseases. Some of the reasons that may explain
262 this phenomenon include remission of seasonal influenza, lack of exposure to
263 environmental factors, greater monitoring of hygiene measures during lockdown in these
264 patients, the significant reduction in air pollution during this period, and/or better control
265 of the disease by improving adherence to treatment due to fear of worsening
266 symptomatology. This trend was already observed since the initial phases of the
267 pandemic in patient populations with other respiratory diseases such as COPD (26).

268 Comorbidities play a major role in the manifestation of COVID-19-related
269 complications. In our study, the manifestation of COVID-19 in patients with asthma was
270 favored by older age, male sex, and the presence of several comorbidities. High blood
271 pressure, dyslipidemia, diabetes, and obesity were the main risk factors for hospital
272 admission due to poor prognosis. The lower risk associated with rhinitis and eczema is

273 consistent with previous observations that allergic sensitization in asthma is linked to
274 lower expression of ACE2 receptors in both upper and lower respiratory airways,
275 suggesting a potential protective effect (27). As previously observed in the general
276 population, mortality due to COVID-19 in patients with asthma mainly occurred in the
277 elderly.

278 The possibility that different therapeutic options in patients with chronic
279 respiratory diseases affects the incidence and prognosis of COVID-19 has been a matter
280 of intense debate. As for asthma, it has been suggested that the use of ICS might yield
281 a protective effect against COVID-19 (28,29). Although an antiviral effect has been
282 described in rhinovirus-induced exacerbations, these results are highly controversial.
283 Peters et al (30) showed an association of ICS use and reduced expression of both ACE2
284 and TMPRSS2 receptors, thus implying that ICS may reduce the risk for SARS-CoV-2
285 infection and decrease COVID-19-related morbidity. Although our data cannot answer
286 this question in a conclusive manner, they show that the proportion of patients who used
287 ICS was significantly reduced in asthmatics who required hospitalization due to COVID-
288 19. These findings are consistent with other studies showing that a combination of
289 glycopyrronium, formoterol, and budesonide prevents the replication of HCoV-229E (via
290 inhibition of receptor expression and/or endosomal function), and that these drugs
291 modulate infection-related inflammation in the respiratory tract (31). In our study, the
292 three cortico-dependent patients in our study diagnosed with COVID-19 did not die from
293 it; however, there is no experimental evidence to date regarding the effect of systemic
294 corticosteroids in patients with asthma and COVID-19.

295 Whether treatment with biologics in patients with asthma impacts SARS-CoV-2
296 infection or the incidence and prognosis of COVID-19 also remains unknown. In this
297 context, there is no evidence supporting that either omalizumab or other drugs that
298 suppress eosinophils directly modulate viral processes in patients with asthma (32,33).
299 In our study, we identified a total of 865 patients treated with biologics. Among these,

300 two patients required admission and only one died from COVID-19; this patient, however,
301 had other comorbidities in addition to severe asthma, which may have contributed to his
302 poor clinical outcome. Overall, our results support the safety of these drugs for the
303 treatment of asthma in patients diagnosed with COVID-19. As with ICS use, our data
304 suggest that biologics might be associated with a protective effect on the clinical course
305 of these patients. However, we cannot rule out that the aforementioned favorable factors
306 also contributed to a better disease prognosis.

307 Our findings are consistent with a recently reported clinical series of 220
308 asthmatic patients with COVID-19 in Chicago and surrounding Illinois suburbs, where
309 asthma was not associated with an increased risk of hospitalization after adjusting for
310 age, sex, gender, and comorbidities (RR of 0.96 [95%CI: 0.77-1.19]) (34). However, ICS
311 use was associated with a non-statistically significant increased risk of hospitalization
312 (RR of 1.39 [95%CI: 0.90-2.15]); in the same report, however, the interpretation of the
313 effects of combined use of ICS and long-acting beta agonists (LABA) and levels of care
314 in these patients was not straightforward. These results warrant further research in
315 patients with asthma and other clinical populations.

316

317 **Strengths and Limitations**

318 The strengths of the present study include immediacy, large sample size, and real-world
319 evidence. In addition, our results must be interpreted in light of the following limitations.
320 First, the main limitation of this type of studies is perhaps the lack of documented
321 information. In Castilla-La Mancha, the digitalization of clinical records has been optimal
322 since 2011. Not only the EHRs system is homogenous throughout the region, but its use
323 has been universal for the past five years. Second, unlike classical research methods,
324 reproducibility is not generally considered in big data studies, since the latter involve
325 large amounts of information collected from the whole target population. Because we

326 exclusively analyzed the data captured in EHRs, the quality of the results reported for
327 some variables is directly tied to the quality of the clinical records; in many cases, EHRs
328 may be partially incomplete and not capture all the relevant clinical information from a
329 given patient. Third, because this study was not designed to collect variables in a strict,
330 *a priori* fashion, there were some variables that were not properly documented and were
331 therefore not analyzed. Finally, our study sample comprised COVID-19 cases confirmed
332 by both PCR/serological tests and clinical criteria (i.e. symptomatology, imaging, and
333 laboratory results). Of note, PCR and other rapid laboratory tests for the detection of
334 SARS-CoV-2 were not routinely used in Spain during the onset of the pandemic. The
335 decision to include clinically diagnosed COVID-19 cases is further supported by recent
336 data questioning the clinical validity and sensitivity of symptom- and image-based
337 identification of patients with COVID-19, especially in the early stages of the disease (35-
338 37).

339

340 **Conclusion**

341 We conclude that *a*) the frequency of SARS-CoV-2 infection has been low in patients
342 with asthma, although higher than in the general population, *b*) the increased risk for
343 hospitalization due to COVID-19 in patients with asthma is largely associated with age
344 and related comorbidities; mortality mainly affected elderly patients, *c*) ICS showed a
345 safe profile; compared to asthmatic patients who required hospitalization due to COVID-
346 19, a significantly higher percentage of non-hospitalized patients used ICS, and *d*)
347 although biologics-treated patients with asthma typically present with the most severe
348 manifestations of the disease, the number of COVID-19-related admissions and mortality
349 in these patients was strikingly low, thus suggesting a protective effect associated with
350 the use of these therapeutic agents.

351

352 REFERENCES

353

- 354 1. The Global Asthma Report 2014. Available at: [http://](http://www.globalasthmareport.org/burden/burden.php)
355 www.globalasthmareport.org/burden/burden.php
- 356 2. GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable
357 health burden of chronic respiratory diseases, 1990-2017: a systematic analysis
358 for the Global Burden of Disease Study 2017. *Lancet Respir Med.* 2020 Jun; 8
359 (6):585-596. doi: 10.1016/S2213-2600(20)30105-3.
- 360 3. Fergeson JE, Patel SS, Lockey RF. Acute asthma, prognosis, and treatment. *J*
361 *Allergy Clin Immunol.* 2017; 139 (2): 438-447. doi: 10.1016/j.jaci.2016.06.054.
362 Epub 2016 Aug 20. Review.
- 363 4. Gibson GJ, Loddenkemper R, Lundbäck B, Sibille Y. Respiratory health and
364 disease in Europe: the new European Lung White Book. *Eur Respir J.* 2013; 42
365 (3):559–63.
- 366 5. Urrutia I, Aguirre U, Sunyer J, Plana E, Muniozguren N, Martínez-Moratalla J, et
367 al. Cambios en la prevalencia de asma en la población española del Estudio de
368 Salud Respiratoria de la Comunidad Europea (ECRHSII). *Arch Bronconeumol.*
369 2007; 43(8):425-30.
- 370 6. Quirce S, Plaza V, Picado C, Vennera M, Casafont J. Prevalence of uncontrolled
371 severe persistent asthma in pneumology and allergy hospital units in Spain. *J*
372 *Investig Allergol Clin Immunol* 2011; 21: 466–71.
- 373 7. Olaguibel JM, Quirce S, Juliá B, Fernández C, Fortuna AM, Molina J, et al.
374 Measurement of asthma control according to Global Initiative for Asthma
375 guidelines: a comparison with the Asthma Control Questionnaire. *Respir Res*
376 2012; 13:50. <https://doi.org/10.1186/1465-9921-13-50>.
- 377 8. Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. *The Lancet* 2018; 391:
378 783–800. [https://doi.org/10.1016/S0140-6736\(17\)33311-1](https://doi.org/10.1016/S0140-6736(17)33311-1)
- 379 9. World Health Organization. Coronavirus disease (COVID-19) outbreak
380 [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen)
381 [they-happen](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen).
- 382 10. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission
383 Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. *New*
384 *England Journal of Medicine.* 2020 Mar 26;382(13):1199-1207. doi:
385 10.1056/NEJMoa2001316.


- 386 11. Chow EJ, Doyle JD, Uyeki TM. Influenza virus-related critical illness: prevention,
387 diagnosis, treatment. *Crit Care*. 2019 Jun 12;23(1):214. doi: 10.1186/s13054-
388 019-2491-9.
- 389 12. Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. Clinical
390 Characteristics of Covid-19 in New York City. *N Engl J Med* 2020.
391 <https://doi.org/10.1056/NEJMc2010419>.
- 392 13. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and
393 mortality in adult COVID-19 inpatients in Wuhan. *J Allergy Clin Immunol* 2020.
394 <https://doi.org/10.1016/j.jaci.2020.04.006>.
- 395 14. Johnston SL. Asthma and COVID-19: is asthma a risk factor for severe
396 outcomes? *Allergy* 2020. <https://doi.org/10.1111/all.14348>.
- 397 15. Mallappallil M, Sabu J, Gruessner A, Salifu M. A review of big data and medical
398 research. *SAGE Open Med*. 2020 Jun 25; 8: 2050312120934839. doi:
399 10.1177/2050312120934839. eCollection 2020
- 400 16. Hernandez Medrano ITG, J; Belda, C; Urena, A; Salcedo, I; Espinosa-Anke, L;
401 Saggion, H. SAVANA: Re-using Electronic Health Records with Artificial
402 Intelligence. *International Journal of Interactive Multimedia and Artificial*
403 *Intelligence*. 2017; 4 (7):8-12.
- 404 17. Espinosa-Anke LT, Pardo A, Medrano I, Ureña A, Salcedo I, Saggion H.
405 SAVANA: A Global Information Extraction and Terminology Expansion
406 Framework in the Medical Domain Procesamiento del Lenguaje Natural.
407 2016; 57: 23-30.
- 408 18. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP;
409 STROBE Initiative. The Strengthening the Reporting of Observational Studies in
410 Epidemiology (STROBE) statement: guidelines for reporting observational
411 studies. *Lancet* 2007; 370: 1453-1457.
- 412 19. Benson T. Principles of Health Interoperability HL7 and SNOMED. London:
413 Springer. 201.
- 414 20. Baeza-Yates RA, Ribeiro-Neto B. 1999. Modern Information Retrieval. Addison-
415 Wesley Longman Publishing Co., Inc., Boston, MA, USA.
- 416 21. Zhang J-J, Dong X, Cao Y-Y, Yuan Y-D, Yang Y-B, Yan Y-Q, et al. Clinical
417 characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China.
418 *Allergy* 2020. <https://doi.org/10.1111/all.14238>.
- 419 22. Liu S, Zhi Y, Ying S. COVID-19 and Asthma: Reflection During the Pandemic.
420 *Clin Rev Allergy Immunol* 2020. <https://doi.org/10.1007/s12016-020-08797-3>.

- 421 23. Gupta A, Bush A, Nagakumar P. Asthma in children during the COVID-19
422 pandemic: lessons from lockdown and future directions for management. *Lancet*
423 *Respir Med* 2020. Published Online June 25, 2020.
424 [https://doi.org/10.1016/S2213-2600\(20\)30278-2](https://doi.org/10.1016/S2213-2600(20)30278-2)
- 425 24. Almonacid Sánchez C, Melero Moreno C, Quirce Gancedo S, Sánchez-Herrero
426 MG, Álvarez Gutiérrez FJ, Bañas Conejero D, et al. PAGE Study: Summary of a
427 study protocol to estimate the prevalence of severe asthma in Spain using big-
428 data methods. *J Investig Allergol Clin Immunol* 2020:0.
429 <https://doi.org/10.18176/jiaci.0483>.
- 430 25. Izquierdo JL, Morena D, Gonzalez Y, Paredero JM, Perez B, Graziani D,
431 Gutierrez M, Rodriguez JM. Clinical Management of COPD in a Real-World
432 Setting. A Big Data Analysis. *Arch Bronconeumol* 2020. 2020 Feb 22; S0300-
433 2896(20)30012-0. doi: 10.1016/j.arbres.2019.12.025. Online ahead of print
- 434 26. Guan W-J, Liang W-H, Zhao Y, et al on behalf of China Medical Treatment Expert
435 Group for COVID-19. Comorbidity and its impact on 1590 patients with COVID-
436 19 in China: a nationwide analysis. *Eur Respir J*. 2020; In press. doi:
437 <https://doi.org/10.1183/13993003.00547-2020>.
- 438 27. Wang R, Bikov A, Fowler SJ. *Thorax* Epub ahead of print. doi:10.1136/thoraxjnl-
439 2020-2151189.
- 440 28. Halpin DMG, Singh D, Hadfield RM. Inhaled corticosteroids and COVID-19: a
441 systematic review and clinical perspective. *Eur Respir J* 2020;55.
442 <https://doi.org/10.1183/13993003.01009-2020>
- 443 29. Grünberg K, Sharon RF, Sont JK, et al. Rhinovirus-Induced airway inflammation
444 in asthma: effect of treatment with inhaled corticosteroids before and during
445 experimental infection. *Am J Respir Crit Care Med* 2001; 164: 1816–22.
- 446 30. Peters MC, Sajuthi S, Deford P, Christenson S, Rios CL, Montgomery MT, et al;
447 National Heart, Lung, and Blood Institute Severe Asthma Research Program-3
448 Investigators. COVID-19 Related Genes in Sputum Cells in Asthma: Relationship
449 to Demographic Features and Corticosteroids. *Am J Respir Crit Care Med*. 2020
450 Apr 29. doi: 10.1164/rccm.202003-0821OC. Online ahead of print.
- 451 31. Yamaya M, Nishimura H, Deng X, Sugawara M, Watanabe O, Nomura K, et al.
452 Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus
453 HCoV-229E replication and cytokine production by primary cultures of human
454 nasal and tracheal epithelial cells. *Respir Investig*. 2020 May;58(3):155-168. doi:
455 10.1016/j.resinv.2019.12.005. Epub 2020 Feb 21.

- 456 32. Esquivel A, Busse WW, Calatroni A, et al. Effects of omalizumab on rhinovirus
457 infections, illnesses, and exacerbations of asthma. *Am J Respir Crit Care Med*
458 2017; 196: 985–92
- 459 33. Sabogal Piñeros YS, Bal SM, van de Pol MA, et al. Anti-IL-5 in mild asthma alters
460 rhinovirus-induced macrophage, B-cell, and neutrophil responses (material). A
461 placebo-controlled, double-blind study. *Am J Respir Crit Care Med* 2019; 199:
462 508–17.
- 463 34. Chhiba KD, Patel GB, Vu THT, et al. Prevalence and characterization of asthma
464 in hospitalized and non-hospitalized patients with COVID-19 [published online
465 ahead of print, 2020 Jun 15]. *J Allergy Clin Immunol.* 2020; S0091-
466 6749(20)30840-X. doi: 10.1016/j.jaci.2020.06.010
- 467 35. Long C, Xu H, Shen Q, Zhang X, Fan B, Wang C, Zeng B, Li Z, Li X, Li H.
468 Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT? *Eur J Radiol*
469 2020; 126: 108961.
- 470 36. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, Tan W. Detection of SARS-CoV-2 in
471 Different Types of Clinical Specimens. *JAMA* 2020.
- 472 37. T, Yang Z, Hou H, Zhan C, Chen C, Lv W, Tao Q, Sun Z, Xia L. Correlation
473 of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in
474 China: A Report of 1014 Cases. *Radiology*: 0(0): 200642.

475 **FIGURES**

476



477

478 **FIGURE 1. Patient Flowchart.** Flowchart depicting the total number (%) of patients with
479 available EHRs, the number of patients with asthma, the number of patients diagnosed
480 with COVID-19, and of those, the number of hospitalizations after diagnosis during the
481 study period (January 1st, 2020-May 10th, 2020). All percent values are computed in
482 relation to the immediately above level.

483 **TABLES**

484 **Table 1. Demographic and clinical characteristics of patients with asthma with/without**
 485 **COVID-19**
 486

	Asthma (n=71,192)	Asthma without COVID-19 (n=70,544)	Asthma with COVID-19 (n=1,006)	OR (95% CI) <i>P</i> value *
<i>Age</i>				
Years (mean ± SD)	42 ± 24	41 ± 24	55 ± 20	< .001
<i>Sex</i>				
Female (%)	59	58	66	1.35 (1.18 – 1.54) <.001
<i>Tobacco use (%)</i>	10	9	11	1.25 (1.03 -1.53) 0.02
<i>Comorbidities</i>				
Arterial Hypertension (%)	24	23	39	2.02 (1.78 - 2.30) <.001
Dyslipidemia (%)	17	16	26	1.85 (1.60 – 2.13) <.001
Diabetes Mellitus (%)	11	11	16	1.54 (1.30 – 1.82) <.001
Obesity (%)	10	9	13	1.35 (1.12-1.62) <.001
Rhinitis (%)	33	33	17	0.42 (0.35 -0.49) <.001
Eczema (%)	7	7	1	0.50 (0.40 – 0.76) <.001

* Patients with asthma with COVID-19 vs. patients with asthma without COVID-19

487

488 **Table 2. Demographic and clinical characteristics of patients with asthma and COVID-19**
 489 **that required a hospital admission.**

490

	Asthma + COVID-19 (n=1,006)	Asthma + COVID-19 Non-Hospitalized (n=743)	Asthma + COVID-19 Hospitalized (n=263)	OR (95% CI) P value *
<i>Age</i>				
Years (mean ± SD)	55 ± 20	52 ± 20	63 ± 18	<.001
<i>Sex</i>				
Female (%)	66	67	61	0.76 (0.57 – 1.02) 0.07
<i>Tobacco use (%)</i>	7	7	6	0.69 (0.37 – 1.29) 0.29
<i>Comorbidities</i>				
Arterial Hypertension (%)	39	34	54	2.27 (1.71 – 3.03) <.001
Dyslipidemia (%)	27	21	38	2.31 (1.70 – 3.13) <.001
Diabetes Mellitus (%)	15	13	21	1.76 (1.22 – 2.54) 0.002
Obesity (%)	13	12	18	1.60 (1.09 – 2.35) 0.02

* Non-hospitalized patients vs. hospitalized patients

491

492 **Table 3. Treatment of patients with asthma and COVID-19: ICS and biologics in hospitalized**
 493 **vs. non-hospitalized patients.**

	Asthma + COVID-19 (Jan. 1 st - May 10 th , 2020)	Asthma + COVID-19 Hospitalized (Jan 1 st -May 10 th , 2020)	P value
<i>Patients with asthma</i> (N = 71.192) (Jan 1 st , 2019 – May 10 th , 2020)	1.006	263	
<i>Asthma + ≥ 1 ICS</i> (N = 42.171; 59,23% of asthmatics)	619	127	<.001
<i>Asthma + ≥ 1 Biologics</i> (N = 865; 1,21% of asthmatics) *	18	2	
Omalizumab (n=641)	9	0	
Mepolizumab (n=308)	7	2	
Benralizumab (n=98)	2	0	
Reslizumab (n=26)	1	0	

* 54% of the patients treated with Mepolizumab had been previously treated with Omalizumab; 65% of patients treated with Benralizumab had previously been treated with Omalizumab and 35% with Mepolizumab. Most of the patients treated with Reslizumab had been previously treated with Omalizumab and Mepolizumab.

494

495 **Table 4. In-hospital mortality in asthmatic patients with / without COVID-19**
496

	Asthma with COVID-19	Asthma without COVID-19	OR (95% CI) <i>P</i> value
<i>Age</i>			
Years (mean ± SD)	78 ± 17	76 ± 17	<.001
<i>Sex</i>			
Female (%)	61	71	0.64 (0.56 – 0.73)
<i>Mortality (%)</i>	2.29	0.54	2.29 (4.35 – 6.66)

497

498

499 **ONLINE APPENDIX**

500

501 **eTable 1. Search terms used to identify patients with bronchial asthma**

- Unstable asthma
- Adult-onset asthma
- Intrinsic asthma
- Asthma attack / Asthma exacerbation
- Acute asthma
- Exercise-induced asthma
- Childhood asthma
- Asthmatic bronchitis
- Cough-variant asthma
- Allergic asthma
- Mild asthma
- Moderate asthma
- Occasional asthma
- Severe asthma
- Chemical-induced asthma
- Substance-induced asthma
- Intermittent asthma
- Seasonal Asthma
- Occupational Asthma
- Chronic obstructive airway disease with asthma
- Asthma with irreversible airway obstruction
- Untreated Asthma
- Persistent asthma
- Induced asthma
- Neutrophilic asthma
- Cortico-dependent asthma

502